The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L01 | Antineoplastic agents | |
3
|
L01E | Protein kinase inhibitors | |
4
|
L01EK | Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors |
| Code | Title | |
|---|---|---|
| L01EK01 | Axitinib | |
| L01EK02 | ||
| L01EK03 | ||
| L01EK04 |
| Active Ingredient |
|---|
|
Axitinib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2 and VEGFR-3. These receptors are implicated in pathologic angiogenesis, tumour growth, and metastatic progression of cancer. Axitinib has been shown to potently inhibit VEGF-mediated endothelial cell proliferation and survival. |
|
Fruquintinib is a selective tyrosine kinase inhibitor of VEGFR-1, -2, and -3 with antitumor effects resulting from suppression of tumour angiogenesis. |
|
Tivozanib potently and selectively blocks all 3 Vascular Endothelial Growth Factor receptors (VEGFR) and has been shown to block various VEGF-induced biochemical and biologic responses in vitro. By blocking VEGF-induced VEGFR activation, tivozanib inhibits angiogenesis and vascular permeability in tumour tissues, leading to inhibition of tumour growth in vivo. |
| Document | Type | Information Source | |
|---|---|---|---|
| FOTIVDA Hard capsule | MPI, EU: SmPC | European Medicines Agency (EU) | |
| FRUZAQLA Hard capsule | MPI, EU: SmPC | European Medicines Agency (EU) | |
| FRUZAQLA Hard capsule | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| INLYTA | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| INLYTA Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) |